Technical Study: Zoetis Inc., Teva Pharma Industries Ltd, Covidien plc, and Valeant Pharma Intl. Inc.
LONDON, August 21, 2013 /PRNewswire/ –
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday August 20, 2013, the S&P 500 ended at 1,652.35, up 0.38% and the NASDAQ
composite closed at 3,613.59, up 0.68%. Shares in healthcare sector companies mostly ended
on a higher note, tracking gains in the broader market. The movers in the sector included
Zoetis Inc. (NYSE: ZTS), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Covidien PLC
(NYSE: COV), and Valeant Pharmaceuticals International Inc. (NYSE: VRX).
AAAResearchReports.com free coverage on ZTS, TEVA, COV, and VRX is available upon
Zoetis Inc.’s stock rose sharply on Tuesday as the broader market edged higher. The
company’s shares traded between $29.71 and $30.41 before closing the day 1.21% higher at
$30.23. A total of 3.80 million shares were traded, which is significantly below the daily
average volume of 9.14 million. The company’s stock has gained 0.70% in the previous three
trading sessions, outperforming the S&P 500 which has declined by 0.54% during the same
period. Download free technical research on ZTS by signing up at:
Shares in Teva Pharmaceutical Industries Ltd fell sharply on Tuesday, extending losses
from previous trading sessions. The company’s shares ended the day at $39.13, down 1.16%,
after fluctuating between $39.10 and $39.69. A total of 3.78 million shares were traded,
which is marginally above the daily average volume of 3.72 million. The company’s shares
have dropped 2.42% in the last one month and 2.64% in the last three months,
underperforming the S&P 500 during the same period. Furthermore, Teva Pharmaceutical
Industries Ltd’s stock is trading marginally above its 200-day moving average of $39.11.
Register now and get access to free analysis on TEVA at:
On Tuesday, Covidien PLC’s stock traded between $60.76 and $61.20 before finishing the
day 0.10% higher at $60.96. A total of 1.70 million shares were traded, which is below the
daily average volume of 2.53 million. The company’s shares have gained 2.25% in the last
three months, outperforming the S&P 500 which has fallen by 0.84% during the same period.
Additionally, Covidien PLC’s shares are trading above their 50-day and 200-day moving
averages. Sign up and read our complimentary report on COV at:
Shares in Valeant Pharmaceuticals International Inc. ended higher on Tuesday, tracking
gains in the broader market. The company’s shares vacillated between $100.78 and $102.45
before finishing the day 0.47% higher at $101.53. A total of 0.80 million shares were
traded, which is below the daily average volume of 1.89 million. The stock has fallen
1.36% in the previous three trading sessions. Despite recent losses, the company’s shares
have gained 11.82% in the last one month and 34.69% in the last three months,
outperforming the S&P 500 which has declined by 2.35%and 0.84% during the same periods.
The free report on VRX can be downloaded by signing up now at:
1) This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2) Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA (R) charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3) This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4) If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5) For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6) Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document,
article or report is prepared and authored by Equity News Network. An outsourced research
services provider has, through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according to the Procedures
outlined by Equity News Network. Equity News Network is not entitled to veto or interfere
in the application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the information
provided in this document. This information is not to be construed as personal financial
advice. Readers are encouraged to consult their personal financial advisor before making
any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake or shortcoming. No liability is
accepted by Equity News Network whatsoever for any direct, indirect or consequential loss
arising from the use of this document. Equity News Network expressly disclaims any
fiduciary responsibility or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Equity News Network does not
(1) guarantee the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The included
information is subject to change without notice.
SOURCE AAA Research Reports